APOA1 and coronary artery disorder: This study presents the development and clinical evaluation of time-resolved fluorescence (TRF) based on direct two-site apoA-I immunoassays (assays 109–121 and 110–525); the assays were established using recombinant apoA-I antibodies previously generated against the intact isolated HDL particles from plasma of patients with CAD (19).